Drug, bio-affecting and body treating compositions inventions

20080103086 - Methods for the treatment of diseases associated with the secretion of hmgb1: The present invention relates to a pharmaceutical composition comprising an antagonist of the phosphorylation of HMGB1, and a method for treating a condition associated with activation of the inflammatory cytokine cascade comprising administering an effective amount of an said antagonist of HMGB1 phosphorylation.... Agent: Jhk Law

20080103088 - Alternative oxidase and uses thereof: The invention relates to a method for combating disorders affecting the mitochondrial oxidative phosphorylation system by allotopic expression of the cyanide-insensitive alternative oxidase (AOX) in human cells. The successful expression of AOX in human cells and in Drosophila has been shown to confer spectacular cyanide-resistance to mitochondrial substrate oxidation, alleviate... Agent: Marshall, Gerstein & Borun LLP

20080103087 - Compositions and methods to control angiogenesis with cuperdoxins: The present invention relates to compositions comprising cupredoxins, and their use to inhibit angiogenesis in mammalian cells, tissues, and animals, and particularly the angiogenesis that accompanies tumor development and particularly in humans. Specifically, the present invention relates to compositions comprising the cupredoxin(s), and or peptides that are variants, derivatives or... Agent: Don J. Pelto Sheppard, Mullin, Richter & Hampton LLP

20080103089 - Compounds, compositions, formulations and process for preparation thereof and method of treatment and management of acidity and related disorders: Novel antacid preparations, methods of preparation of the same and a method of treating acidity related disorders using the said novel antacid composition are described. The antacid composition of this invention are based on use of proteins and their derivatives including their hydrolysates and enzymatic treatment products such as plasteins... Agent: Nath & Associates

20080103091 - Bi-functional peptides for multiple sclerosis treatment and diagnosis: Novel bifunctional peptides useful in the treatment and/or diagnosis of EAE or MS. The peptides have a first peptide portion derived from an epitope of myelin proteolipid protein, myelin oligodendrocyte glycoprotein, or oligodendrocyte-specific peptide and a second peptide portion derived from CD11a (LFA-1 alpha subunit), CD18 (LFA-1 beta subunit), CD154... Agent: Stinson Morrison Hecker LLP Attn: Patent Group

20080103097 - Glp-1 derivatives ii: The present invention relates to a derivative of GLP-1(7-C), wherein C is 35 or 36 which derivative has just one lipophilic substituent which is attached to the C-terminal amino acid residue.... Agent: Novo Nordisk, Inc. Patent Department

20080103096 - Muteins of fibroblast growth factor 21: The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced capacity of O-glycosylation when expressed in yeast compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of... Agent: Eli Lilly & Company

20080103095 - Stress protein compositions and methods for prevention and treatment of cancer and infectious disease: Pharmaceutical compositions comprising a stress protein complex and related molecules encoding or cells presenting such a complex are provided. The stress protein complex comprises an hsp110 or grp170 polypeptide complexed with an immunogenic polypeptide. The immunogenic polypeptide of the stress protein complex can be associated with a cancer or an... Agent: Karen S. Canady Canady & Lortz LLP

20080103103 - Reagents and methods to treat ocular diseases and infection: The invention provides compositions and methods of treating an ocular condition by administering to an eye of a patient having an ocular condition an effective amount of a catechin or polyphenol. The compositions and methods can be used to treat ocular conditions such as ocular infection, ocular inflammation, ocular cancer... Agent: Mcdermott, Will & Emery

20080103106 - Compositions and their uses directed to il-4r alpha: Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to... Agent: Knobbe, Martens, Olson & Bear, LLP

20080103107 - Screening methods: The present invention provides materials and methods relating to screening for compounds useful in the treatment of Alzheimer's disease and related conditions. In particular, screening methods using tyrosine kinases are provided, as are methods relating to the role of tyrosine kinases as therapeutic targets.... Agent: Dann, Dorfman, Herrell & Skillman

20080103108 - Targeted artificial gene delivery: Novel and improved compositions and methods for gene therapy are provided. In particular, a targeted artificial gene delivery (“TAGD”) vehicle is provided, comprising a multifunctional artificial surface moiety surrounding a recombinant viral particle (nucleocapsid) or recombinant core for gene delivery.... Agent: Ropes & Gray LLP

20080103110 - Compounds: The invention provides a water-soluble prodrug compound comprising a therapeutically effective moiety coupled via a metabolically cleavable bond to a protein binding moiety, wherein said therapeutically effective moiety has an anticancer, antiinflammatory, antiinfective or antipain effect, said protein binding moiety binds non-covalently to blood proteins, and the protein binding of... Agent: Sughrue Mion, PLLC

20080103111 - Smoking cessation treatment with appetite suppression: A multi-component compound for the simultaneous treatment of nicotine addiction and the side effects of nicotine withdrawal, such as excessive appetite. The first component is a bivalent negative sulfur compound in an amount effective to control nicotine craving or the withdrawal symptoms resulting from nicotine withdrawal. The bivalent negative sulfur... Agent: John C. Smith, Esq.

20080103114 - Use of diindolylmethane-related indoles for the treatment and prevention of respiratory syncytial virus associated conditions: The present invention includes compositions and methods for the treatment and prevention of conditions associated with Respiratory Syncytial Virus (RSV) infection. RSV-associated conditions include acute infections in mammals, typically bronchiolitis and pneumonia, and post-infectious chronic respiratory conditions. In particular, the present invention describes new therapeutic and preventative uses for 3,3′-diindolylmethane... Agent: Jones Day

20080103090 - Human secreted proteins: The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating cancer and other hyperproliferative diseases and disorders. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080103092 - Methods for intradermal, transdermal or transmucosal delivery of biologically active substances: This invention relates to method for intradermal, transdermal or transmucosal delivering a biologically active substance to a mammal in need thereof, which method comprises a step of co-administering to said mammal with the biologically active substance an effective amount of an absorption enhancer, which is water comprising from about 99.760... Agent: Notaro And Michalos

20080103093 - Methods of treating cartilage defects: The present invention provides methods of repairing and regenerating cartilage tissue by administering into the cartilage or the area surrounding the cartilage a composition comprising a therapeutically effective amount of a morphogenic protein.... Agent: Ropes & Gray LLP

20080103094 - Targeted delivery of drugs for the treatment of viral infections: Conjugates of transferrin or transcobalamin with anti-viral agents are useful in the treatment of viral infections. Suitable anti-viral agents include apoptosis inducing compounds, compounds which inhibit the replication of the virus, a cytotoxic antibiotic, an alkylating agent, a plant toxin, and a bacterial mutant toxin. Transferrin or transcobalamin is preferably... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080103099 - Apoptin-associating protein: The invention relates to the field of apoptosis. The invention provides novel therapies, for example, novel combinatorial therapies or novel therapeutic compounds that can work alone, sequentially to, or jointly with Apoptin, especially in those cases wherein p53 is completely or partially non-functional.... Agent: Trask Britt

20080103098 - Recombinant expression of proteins in a disulfide-bridged, two-chain form: Polypeptides or proteins are produced as a disulfide bridged dichain by recombinant expression in E. coli host cells and exert biologic activity as such a dichain. A C-terminal amino acid of the first chain is Arg or Lys. The second chain has N-terminally 1 to 20 amino acid residues and... Agent: Gudrun E. Huckett Draudt

20080103100 - Materials and methods for the treatment of celiac disease: The present invention provides materials and methods for the treatment of celiac disease. In addition, the present invention provides materials and methods of monitoring the treatment of a subject having celiac disease.... Agent: Connolly Bove Lodge Hutz, LLP (for Alba Therapeutics)

20080103101 - Ku-70-derived bax-suppressing peptides and use thereof for the protection of damaged cells: A method of protecting cells from cell death comprising the step of supplying to the cell an effective amount of a Bax-inhibiting peptide is disclosed.... Agent: Quarles & Brady LLP

20080103102 - Therapeutic compositions and methods of treatment with capsianoside-type compounds: The present invention discloses the use of certain compounds as therapeutic agents, and in particular as analgesics and anti-inflammatory agents. Such compounds include, for example, certain diterpene monoglycosides and diterpene diglycosides. The compounds of the present invention may be synthesized or isolated from the fruit of the genus Capsicum, and... Agent: Keith R. Lange

20080103104 - Treatment of cancer: The present invention provides compositions of matter, kits and methods for their use in the treatment of cancer. In particular, the invention provides compositions and methods for treating cancer in a subject by inhibiting a poly-ADP-ribose polymerase, as well as providing formulations and modes of administering such compositions.... Agent: Wilson Sonsini Goodrich & Rosati

20080103105 - Hmg coa reductase mediated modulation of neurogenesis: The instant disclosure describes methods of treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of an HMGCR modulating agent, optionally in combination with one or more other neurogenic agents,... Agent: Townsend And Townsend And Crew, LLP

20080103109 - Vectors for tissue-specific replication: The invention generally relates to targeted gene therapy using recombinant vectors and particularly adenovirus vectors. The invention specifically relates to replication-conditional vectors and methods for using them. Such vectors are able to selectively replicate in a target tissue to provide a therapeutic benefit from the presence of the vector per... Agent: Ropes & Gray LLP

20080103112 - Glucan preparations: Particulate β-glucan is solubilized at elevated pressure and temperature to form soluble β-glucan. The method is safe and economical and produces a product that is an improved pharmaceutical agent.... Agent: Biopolymer Engineering , Inc. Dba Biothera , Inc

20080103113 - Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex: The present invention relates to methods to use non-steroidal ligands in nuclear receptor-based inducible gene expression system to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising:... Agent: Sughrue Mion, PLLC

20080103115 - Phosphonate compounds: The present invention relates to phosphonate compounds, compositions containing them, processes for obtaining them, and their use for treating a variety of medical disorders, e.g., osteoporosis and other disorders of bone metabolism, cancer, viral infections, and the like.... Agent: Dla Piper US LLP

20080103116 - Method of treatment and compositions of d-chiro inositol and phosphates thereof: The present invention relates to the use of D-chiroinositol or a phosphate thereof in combination with folate for the reduction or prevention of congenital deformations such as anorectal malformations, neural tube defects, cleft-lip, cleft palate, and other birth defects. The invention further relates to the use of D-chiroinositol or a... Agent: Irving M. Fishman C/o Cohen, Tauber Spievack & Wagner

20080103117 - Treatment product for animals and means for preparing same: e

20080103118 - Composition for improving blood cholesterol levels: A nutritional composition for improving blood cholesterol by jointly and simultaneously inhibiting cholesterol absorption, decreasing blood LDL levels, increasing blood HDL levels and interfering with HMG-CoA reductase synthesis or degradation in an individual comprising, therapeutically effective amounts of plant sterols or plant stanols or derivatives thereof, procyanidins, policosanol and niacin... Agent: Torys LLP

20080103119 - Carbonate and carbamate modified forms of glucocorticoids in combination with b2 adrenergic agonists: n

20080103120 - Pharmaceutical composition: A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic... Agent: Synnestvedt & Lechner, LLP

20080103121 - Cephalosporin derivative formulation: The present invention relates to a freeze-dried formulation for cephalosporin derivatives having increased stability and a method for preparing such a formulation using certain excipients for stabilizing the formulation.... Agent: Philip S. Johnson Johnson & Johnson

20080103122 - Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis: A pharmaceutical combination comprising an effective amount of at least one cholesterol absorption inhibitor and at least one microsomal triglyceride transfer protein inhibitor (MTP).... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20080103124 - Cefdinir-containing pharmaceutical composition: A pharmaceutical composition with an enhanced bioavailability, particularly improved an oral absorption, comprising cefdinir or a pharmaceutically acceptable salt thereof and aminoalkyl methacrylate copolymer E is disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080103125 - Heterocylic antiviral compounds: Chemokine receptor antagonists, in particular, 3,7-diazabicyclo[3.3.0]octane compounds according to formula (I) wherein R1-R3 and Ar are as defined herein are antagonists of chemokine CCR5 receptors which are useful for treating or preventing an human immunodeficiency virus (HIV) infection, or treating AIDS or ARC. The invention further provides methods for treating... Agent: Roche Palo Alto LLC Patent Law Dept. M/s A2-250

20080103126 - Medicinal compositions improving brain function and method for improving brian function: wherein R1, R2, R3, R4, m and n are as defined in the specification, or salts thereof exhibits synergistically improved anti-hypoxic activity when combined with a compound having an acetylcholine esterase inhibitory activity. Therefore, the combination according to the present invention is useful as a method for improving cerebral function.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080103123 - New compounds: and pharmaceutically acceptable salts, hydrates, geometrical isomers, racemates, tautomers, optical isomers and N-oxides thereof, wherein one of W1 and W2 is N and the other is CR12. The invention also relates to pharmaceutical compositions comprising these compounds, and to the use of these compounds for the prophylaxis and treatment of... Agent: Edwards Angell Palmer & Dodge LLP

20080103127 - Methods for treating disruptive behavior disorders: d

20080103128 - Lactams substituted by cyclic succinates as inhibitors of abetta protein production: to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of... Agent: Kelley Drye & Warren LLP

20080103129 - Heterocyclic derived metalloprotease inhibitors:

20080103130 - Benzazepin-2(1h)-one derivatives:

20080103131 - Therapeutically active thiophenepyrimidinone compounds and their use: Thiopheneprymidinone compounds useful in therapy, especially for use in the treatment and/or prevention of a steroid hormone dependent disorder, preferably a steroid hormone dependent disease or disorder requiring the inhibition of a 17β-hydroxysteroid dehydrogenase (17β-HSD) such as 17β-HSD type 1, type 2 or type 3 enzyme.... Agent: Crowell & Moring LLP Intellectual Property Group

20080103132 - Fused heterocyclic compounds: Certain fused pyrrole- and pyrazole-containing heterocyclic compounds are serotonin modulators useful in the treatment of serotonin-mediated diseases.... Agent: Philip S. Johnson Johnson & Johnson

20080103133 - 4-oxo-2,3,4,5-tetrahydro-benzo[b][1,4]diazepine derivatives: r

20080103134 - Use of selected cgrp-antagonists in combination with other antimigraine drugs for the treatment of migraine: The present invention relates to a process for the treatment or prevention of indications which are selected from among the group comprising headaches, migraine and cluster headaches, this process comprising the joint administration of a therapeutically effective amount of a selected CGRP antagonist (A), a physiologically acceptable salt thereof or... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080103135 - Phenylalkynes: Substituted phenylalkynes of formula (I), compositions containing them, and methods of making and using them to treat histamine-mediated conditions.... Agent: Philip S. Johnson Johnson & Johnson

20080103136 - Novel fused imidazole derivative: b

20080103137 - Deazapurines and uses thereof:

20080103138 - Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions: wherein the groups R1 to R4 have the meanings given in the claims and specification, the tautomers, racemates, enantiomers, diastereomers, solvates, hydrates, mixtures thereof, the prodrugs thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, methods of preparing these compounds and... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080103139 - 3-carbamoyl-2-pyridone derivative: e

20080103142 - Benzotriazole kinase modulators:

20080103140 - Cyclohexylamides as dopamine d3, d2 and 5ht1a antagonists: The present invention relates to new dopamine D3 and D2 and serotonin 5-HT1A receptor subtype preferring ligands of formula (I); wherein A represents alkyl, alkenyl, aryl, heteroaryl, cycloalkyl or a group of formula —NR1R2, wherein R1 and R2 represent independently a substituent selected from hydrogen, alkyl, alkenyl, aryl, heteroaryl or... Agent: Darby & Darby P.C.

20080103141 - New compounds: and pharmaceutically acceptable salts, hydrates, geometrical isomers, racemates, tautomers, optical isomers and N-oxides thereof, wherein W1 and W3 are N and W2 and W4 are CR12, or W1 and W3 are CR12 and W2 and W4 are N. The invention also relates to pharmaceutical compositions comprising these compounds, and to... Agent: Edwards Angell Palmer & Dodge LLP

20080103143 - Novel heteroaryl carboxamides: d

20080103144 - Fungicidal mixtures based on amide compounds and morpholine or piperidine derivatives:

20080103145 - Highly selective norepinephrine reuptake inhibitors and methods of using the same: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. Examples of such compounds include reboxetine, and more particularly racemic reboxetine. The methods generally include administration of... Agent: James J. Napoli Marshall O'toole Gerstein Murray & Borun

20080103146 - Highly selective norepinephrine reuptake inhibitors and methods of using the same: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about... Agent: James J. Napoli Marshall O'toole Gerstein Murray & Borun

20080103147 - Highly selective norepinephrine reuptake inhibitors and methods of using the same: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. Examples of such compounds include reboxetine, and more particularly racemic reboxetine. The methods generally include administration of... Agent: James J. Napoli Marshall O'toole Gerstein Murray & Borun

20080103148 - Cyclic pyrazinoylguanidine sodium channel blockers: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080103149 - Novel tetracyclic inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applications: e

20080103150 - Triazoles as farnesyl transferase inhibitors: a prodrug, N-oxide, addition salt, quaternary amine or stereochemically isomeric form thereof, wherein L1 and L2 are R1—Y— wherein each (R1—Y)— substituent is defined independently of the other; Y is C1-4alkanediyl, C2-4alkenediyl, C2-4alkynediyl, C(═O), or a direct bond; R1 is hydrogen, cyano, aryl or a substituted or unsubstituted C1-14heterocycle; =Z1-Z2=Z3-... Agent: Philip S. Johnson Johnson & Johnson

20080103151 - Heterocyclic compounds and their uses as therapeutic agents: This invention is directed to heterocyclic compounds that are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of using the compounds are also disclosed.... Agent: Seed Intellectual Property Law Group PLLC

20080103152 - Novel diazabicyclononene derivative: The invention relates to a novel 3,9-diazabicyclo[3.3.1]nonene derivative and the enantiomers thereof and the use thereof as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing at least one compound of formula (I) or... Agent: Thomas Hoxie

20080103153 - Combination of brimonidine and timolol for topical ophthalmic use: Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.... Agent: Allergan, Inc.

20080103154 - 3, 4-dihydro-2(ih)-quinolinone and 2(1h)-quinolinone derivatives: The present invention relates to novel 3,4-dihydro-2(1H)-quinolinone and 2(1H)-quinolinone derivatives, their acceptable acid addition salts, solvates, hydrates and polymorphs thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by atypical antipsychotic agents.... Agent: Edwards Angell Palmer & Dodge LLP

20080103155 - Pharmaceutical compositions for the treatment of sexual disorders ii: The invention relates to new pharmaceutical compositions for the treatment of sexual disorders and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment of... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080103156 - Bicyclic heteroaromatic compounds: e

20080103158 - Methods for treating delaying the progression of alzheimer's disease with heterocyclic compounds: Disclosed is an antidepressant, neuroprotectant, amyloid β deposition inhibitor, or age retardant composition containing a heterocyclic compound having the general formula (I):... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080103157 - Methods for treating depression, neurodegeneration, inhibiting amyloid beta deposition, delaying senescence, and extending life spans with heterocyclic compounds: Disclosed is an antidepressant, neuroprotectant, amyloid β deposition inhibitor, or age retardant composition containing a heterocyclic compound having the general formula (I):... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080103159 - Composition comprising ocaperidone: The present invention relates to a composition comprising ocaperidone as an active substance and an effective amount of water-soluble polymers to increase solubility of ocaperidone. The present invention further relates to a therapeutic system for ocaperidone with a compartment for the drug formulation comprising said composition, and to a process... Agent: Philip S. Johnson Johnson & Johnson

20080103160 - Protein phosphatase inhibitors: A method of inhibiting protein tyrosine phosphatase in a subject includes administering to the subject a therapeutically effective amount of at least one benzo-1,4-quinone, phenyl isothiazolone, or analog thereof to the subject.... Agent: Tarolli, Sundheim, Covell & Tummino L.L.P.

20080103161 - Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof: Ra, Rb, Rc, A, B, C, D, E and X are defined as in claim 1, the tautomers, the stereoisomers, the mixtures and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080103162 - Antipruritics: The present invention relates to an antipruritic agent comprising a nociceptine antagonist as an active ingredient. The nociceptine antagonist can be used as a preventive or remedy for diseases associated with itching (for example, atopic dermatitis and urticaria), local pruritus cutaneous caused by insect excretion and secretion, nodular prurigo, kidney... Agent: Dreier LLP

20080103163 - Antipruritics: The present invention relates to an antipruritic agent comprising a nociceptin antagonist as an active ingredient. The nociceptin antagonist can be used as a preventive or remedy for diseases associated with itching (for example, atopic dermatitis and urticaria), local pruritus cutaneous caused by insect excretion and secretion, nodular prurigo, kidney... Agent: Dreier LLP

20080103164 - Useful compounds for hpv infection: The present invention relates to compounds that are useful in the treatment of human papillomaviruses, and also to the methods for the making and use of such compounds.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080103165 - Ppar mediated modulation of neurogenesis: The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system including by stimulating or increasing neurogenesis, neuroproliferation, and/or neurodifferentiation. The disclosure includes compositions and methods based on use of a peroxisome proliferator-activated receptor (PPAR) agent, optionally in combination with one or more other... Agent: Townsend And Townsend And Crew, LLP

20080103166 - Remedy for psychoneurotic diseases: A medicinal preparation for preventing and/or treating psychoneurotic diseases such as integration dysfunction and Alzheimer's disease which contains tropisetron or its pharmaceutically acceptable salt as the active ingredient.... Agent: Wolf Greenfield & Sacks, P.C.

20080103168 - Novel 3-thia-10-aza-phenanthrene derivatives: m

20080103167 - Sulfonamide-thiazolpyridine derivatives as glucokinase activators useful the treatment of type 2 diabetes: The present invention provides compounds of the formula (I), which are activators of glucokinase activity and, thus, may be employed as therapeutic agents for the treatment of glucokinase mediated conditions. Accordingly, the compounds of formula (I) may be employed for the prevention and the treatment of impaired glucose tolerance, Type... Agent: Novartis Institutes For Biomedical Research, Inc.

20080103169 - Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same: The present disclosure relates to pharmaceutical compositions comprising combinations of proton pump inhibitors, their salt forms or related compounds and at least one other pharmaceutically active agent. Methods of using such compositions, including methods of and an apparatus for administering such compounds, are also provided... Agent: Mayer Brown LLP

20080103170 - Nicotinic acetylcholine receptor ligands: e

20080103171 - Stable particular pharmaceutical composition of solifenacin or salt thereof: The present invention relates to the provision of a stable particulate pharmaceutical composition of solifenacin or a salt thereof, which is in a spherical shape suitable for coating and in which degradation with time can be inhibited when a pharmaceutical preparation of solifenacin or a salt thereof is supplied to... Agent: Sughrue-265550

20080103172 - Imidazole substituted pyrazole kinase inhibitors: e

20080103173 - Compounds having activity at nk3 receptor and uses thereof in medicine:

20080103175 - 7-((1h-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline:

20080103174 - Ether derivatives:

20080103176 - Substituted hydroxyethylamines: This invention is directed to compounds of the formula (I), as defined herein. The compound of formula I may be used, for example, to treat a disorder or condition that may be treated by inhibiting 13-secretase.... Agent: Pfizer Inc Steve T. Zelson

20080103177 - New use of iloperidone: The invention relates to the use of iloperidone in the treatment of affective disorders, including bipolar mood disorders.... Agent: Hoffman Warnick & D'alessandro, LLC

20080103178 - N-dihydroxyalkyl-substituted 2-oxo-imidazole derivatives: in which, R stands for a dihydroxy-substituted C1-C6 alkyl group, and Cy stands for an optionally substituted C6-C10 bi- or tri-cyclic aliphatic carbocyclic group. These compounds act as nociceptin receptor antagonist, and are useful, for example, as relievers against tolerance to narcotic analgesic, dependence on narcotic analgesic or addiction; analgesic... Agent: Merck And Co., Inc

20080103179 - Combination therapy: The present invention features a novel therapy for treating diabetes, hypertension, migraine, epilepsy, sleep apnea, depression, impulse control disorders or alcohol addiction which involves treating a subject with a sympathomimetic agent (e.g., phentermine or a phentermine-like drug) in combination with an anticonvulsant sulfamate compound (e.g., topiramate) or an anticonvulsive sulfonylurea... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20080103180 - Ccr9 inhibitors and methods of use thereof: The invention relates to compounds represented by Structural Formula I, which can bind to CCR9 receptors and block the binding of a ligand (e.g., TECK) to the receptors. The invention also relates to a method of inhibiting a function of CCR9, and to the use compounds represented by Structural Formula... Agent: Millennium Pharmaceuticals, Inc.

20080103181 - Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases: Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases cased by the orthopoxvirus.... Agent: Bingham Mccutchen LLP

20080103182 - Indazole derivatives: t

20080103183 - New imidazolone and imidazolidinone derivatives as 11b-hsd1 inhibitors:

20080103184 - Compositions and methods for treating hair loss using non-naturally occurring prostaglandins: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.... Agent: Michael Best & Friedrich LLP

20080103185 - Process for producing thiazolidinedione compound and production intermediate thereof: As described above, a process for producing a compound represented by the general formula (A) or a salt thereof, comprising converting 4-[(2,4-dioxothiazolidin-5-yl)methyl]phenoxyacetic acid represented by the following formula into a compound of the general formula (I), wherein X=a halogen atom; then reacting the compound with a compound represented by the... Agent: Frishauf, Holtz, Goodman & Chick, PC

20080103186 - Novel crystalline forms of an antiviral benzimidazole compound: The invention relates to crystalline forms of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H benzimidazole, pharmaceutical compositions comprising the same, processes for preparing the same, and their use in medical therapy.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080103187 - Tgf-beta gene expression inhibitor: A TGF-β gene expression inhibitor containing a pyrrole-imidazole polyamide having N-methylimidazole unit (hereinafter also referred to as Py), N-methylimidazole unit (hereinafter also referred to as Im) and γ-aminobutyrate unit which can be holded into an U-shaped conformation at the γ-aminobutyrate unit in the minor groove in a double helix region... Agent: Birch Stewart Kolasch & Birch

20080103188 - Novel bicyclic compounds as modulators of androgen receptor function: T

20080103189 - Preparation and utility of substituted indoles: Disclosed herein are substituted indoles of Formula I, processes of preparation there of, pharmaceutical compositions thereof, and methods of their use there of.... Agent: Global Patent Group - Apx Ms. Lavern Hall

20080103190 - Thrombopoietin activity modulating compounds and methods: Disclosed herein are compounds, pharmaceutical compositions comprising the same, methods of modulating the activity a thrombopoietin receptor using the same, methods of identifying compounds as thrombopoietin receptor modulators, and methods of treating disease by administering a compound of the invention to a patient in need thereof.... Agent: Knobbe Martens Olson & Bear LLP

20080103191 - Entacapone-derivatives: Pharmaceutical composition comprising one or more entacapone derivatives and one or more pharmaceutically acceptable carriers, a process for producing the pharmaceutical composition, specific entacapone derivatives, a process for the preparation of entacapone derivatives, and the use of the entacapone derivatives for the preparation of a medicament.... Agent: Harness, Dickey & Pierce, P.L.C

20080103192 - Conjugates of artemisinin-related endoperoxides and hydrazone derivatives for the treatment of cancer: Compounds having an artemisinin-related endoperoxide moiety covalently coupled to a hydrazone moiety through a linker. Compositions and methods for treating cancer using the compounds.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20080103193 - Methods for making compositions and compositions for treating pain and cachexia: The present invention pertains to methods for making compositions and compositions for treating pain and cachexia or AIDS wasting. In particular, the instant invention employs methods for making Δ9-tetrahydrocannabinol (Δ9-THC) and Δ9-tetrahydrocannabinolic acid (Δ9-THCA) from Cannabis sativa, and compositions for the treatment of these diseases.... Agent: Aphios Corporation

20080103194 - Anti-first-pass effect compounds: Safe, effective first-pass inhibiting compounds and citrus-derived substances are provided. Formulations containing the compounds are also provided as are methods for inhibiting the first pass effect.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20080103195 - Compounds from antrodia camphorata for inhibiting the growth of cancer tumor cells: The present invention relates a compound for inhibiting the growth of tumor cells. More specifically, the compound of the present invention is 4,7-dimethoxy-5-methy-1,3-benzodioxole. 4,7-dimethoxy-5-methy-1,3-benzodioxole of the present invention is used for inhibiting the growth of tumor cells of breast cancer, liver cancer, and prostate cancer, and the pharmaceutical composition comprises... Agent: Birch Stewart Kolasch & Birch

20080103196 - Novel diterpenes from the fruiting body of antrodia camphorata and pharmaceutical compositions thereof: e

20080103197 - Alkyl-, alkenyl- and alkynylcarbamate derivatives, their preparation and their application in therapeutics:

20080103198 - Methods for treatment of cochlear and vestibular disorders: wherein phenyl is substituted at X with one to five halogen atoms selected from the group consisting of fluorine, chlorine, bromine and iodine; and, R1, R2, R3, R4, R5 and R6 are independently selected from the group consisting of hydrogen and C1-C4 alkyl; wherein C1-C4 alkyl is optionally substituted with... Agent: Philip S. Johnson Johnson & Johnson

20080103199 - Treatment of pervasive developmental disorders: e

20080103200 - Levodopa prodrugs, and compositions and uses thereof: Prodrugs of levodopa, methods of making prodrugs of levodopa, methods of using prodrugs of levodopa, and compositions of prodrugs of levodopa are disclosed.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080103201 - Novel alpha-glucosidase inhibitor from tabernaemontana dichotoma: This invention is directed to a novel pharmacological property of β-Amyrin acetate derived from Tabernaemontana dichotoma as a potent α-glycosidase inhibitor, which has not been reported before. The present discovery also provides for the use of this compound as a new oral hypoglycemic drug in the treatment of type II... Agent: Sarfaraz K. Niazi

20080103202 - Method of preparing creatine ester salts and uses thereof.: This invention discloses the method of preparation of creatine ester-salts. Creatine is an extremely popular ergogenic aid, and is found most often in the form of creatine monohydrate. Creatine monohydrate is poorly soluble in water however and while esters gain solubility, there functionality is greatly decreased. The material can be... Agent: Amin Hallihan, LLC

20080103203 - Skin disinfectant: The skin disinfectant, which is able to sterilize skin by the action of a surfactant without damaging skin health conditions, contains water, from which polyvalent cations are removed and to which a sodium ion is added, and a surfactant. The surfactant is, for example, a fatty acid salt. When the... Agent: Birch Stewart Kolasch & Birch

20080103204 - Method of modulating cellular activity and agents useful for same: Described is a rational design of therapeutic and/or prophylactic methods of treating conditions characterized by aberrant or otherwise unwanted microglial cell functioning and rational design methods for treating a range of neurological disorders which are characterized by nitric oxide induced neuronal damage.... Agent: Bozicevic, Field & Francis LLP

20080103205 - Pesticidal compositions and methods of use: The present invention provides methods of protecting plants and other multicellular organisms from pests. The methods use substituted organic acid or substituted anthracene compounds, which act to alter the activity of one or more anion transporters in the pests. Among the pests treated are nematodes and insects. Methods of screening... Agent: Latimer, Mayberry & MatthewsIPLaw, LLP

20080103206 - Acetaminophen / ibuprofen combinations and method for their use: A pharmaceutical dosage form is provided comprising a non-steroidal anti-inflammatory agent and acetaminophen, and methods for their use. In one embodiment, the dosage form is comprised of ibuprofen and acetaminophen as the sole pharmaceutically effective agents, wherein the ibuprofen and acetaminophen are in a weight ratio of about 12 parts:about... Agent: Philip S. Johnson Johnson & Johnson

20080103207 - Topical ceramide compositions and methods of use: Ceramide NS and butylene glycol can form a topical composition in which the ceramide NS is lamellar. The topical compositions can be used in a formulation such as a lotion, gel, or cream and can be used to treat an aging-related skin condition, dry skin, skin irritation, skin wrinkles, or... Agent: Darby & Darby P.C.

20080103208 - Inhibition of fatty acid synthesis by parp inhibitors and methods of treatment thereof: The present invention relates to a method of treating a fatty acid synthesis related disease comprising administering to a patient in need thereof an effective amount of a PARP inhibitor or metabolite thereof to inhibit fatty acid synthesis, wherein the fatty acid synthesis related disease is obesity, diabetes, or cardiovascular... Agent: Wilson Sonsini Goodrich & Rosati

20080103209 - Compounds and methods for treating non-inflammatory pain using ppar alpha agonists: Compositions and methods for treating noninflammatory pain, including but not limited to, neuropathic pain by using peroxisome proliferator activated receptor a (PPARa) agonists to treat a subject having such pain are described. The agonists may be used with additional therapeutic agents such as an inhibitor of fatty acid amide hydrolase... Agent: Townsend And Townsend And Crew, LLP

20080103210 - wide spectrum disinfectant: The invention discloses methods of making and uses for wide spectrum disinfectants including as components an alcohol, O-phenylphenol, chlorhexidine gluconate, nonoxynol-9, benzalkonium chloride, and deionized double distilled water wherein on a weight/volume ratio the alcohol comprises from 50% to 80%, the O-phenylphenol comprises from 0.1% to 0.8%, the chlorhexidine gluconate... Agent: Porter, Wright, Morris & Arthur LLP Attn: Intellectual Property Department

20080103211 - Use of beta-adrenoceptor antagonists for the manufacture of a medicament for the treatment of disorders of the outer retina: Compositions and methods for treating disorders of the outer retina with β-adrenoceptor antagonists are disclosed.... Agent: Alcon

20080103212 - Treatment of fruit in storage facility with solid derived diphenylamine anti scald agent: Techniques for melting and forming aerosols from solid diphenylamine are disclosed. Solid diphenylamine in block, flake or powder form is convenient to ship and to handle. Solid diphenylamine is melted by controlled techniques to form a substantially pure liquid stream of diphenylamine. The molten or liquid stream of diphenylamine is... Agent: Steven D. Boyd Arkema Inc.

20080103213 - Liposomal curcumin for treatment of neurofibromatosis: The present invention provides a compositions and methods for the treatment of Neurofibromatosis Type 1 and 2, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system to target... Agent: Chalker Flores, LLP

20080103214 - Novel composition for easing human childbirth: The present invention relates to a composition having a lubricant effect for use in particular during human vaginal delivery.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080103215 - Screening method: The present invention provides a method of screening a compound or its salt that alters binding properties of a protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof, and a ligand capable of... Agent: Edwards Angell Palmer & Dodge LLP

20080096792 - Peptide and a derivative thereof promoting cell adhesion and spreading: The present invention relates to a peptide promoting cell adhesion and spreading, fragments, and derivatives thereof, more particularly, integrin-α3β1-dependent peptide in human laminin-5 α3 chain LG3 domain, mediating integrin α3β1 binding and cell adhesion and spreading, fragments and derivatives thereof. The inventive peptide, fragments and derivatives thereof can be used... Agent: Intellectual Property / Technology Law

20080096798 - Method for promoting hard tissue formation: Formulations and methods to promote biological processes to form or regenerate new hard tissues such as bones, cartilage, and/or dental tissues are disclosed. The formulation comprising two proteins is administered to enhance biological activities of a hard tissue growth and differentiation factor characterized by specific and selective upregulation and/or extension... Agent: Bozicevic, Field & Francis LLP

20080096805 - Nitric oxide-blocked cross-linked tetrameric hemoglobin: The present invention includes compositions containing carboxamidomethylated cross-linked hemoglobin where the cysteine moiety of the hemoglobin includes a thiol protecting group and where the hemoglobin has a reduced ability to bind with nitric oxide. Preferably, the hemoglobin is deoxygenated, endotoxin free, and stroma free. The present invention also includes method... Agent: Wilson Sonsini Goodrich & Rosati

20080096810 - Cab molecules: The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in therapy.... Agent: Victoria L. Boyd Genencor International

20080096809 - Diastereomeric peptides useful as inhibitors of membrane protein assembly: The present invention relates to membrane binding diastereomeric peptides comprising amino acid sequences corresponding to a fragment of a transmembrane proteins, wherein at least two amino acid residues of the diastereomeric peptides being in a D-isomer configuration. The diastereomeric peptides are useful in inhibiting fusion membrane protein events, including specifically... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20080096811 - Selective vpac2 receptor peptide agonists: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.... Agent: Eli Lilly & Company

20080096833 - Polytpeptide specific to liver cancer, polynucleotide coding for the polypeptide, and rna molecule inhibiting expression of the polypeptide: There are provided a polypeptide specific to liver cancer, a polynucleotide coding for the polypeptide, and an RNA molecule suppressing the expression of the polypeptide. The present invention is particularly intended for a polypeptide comprising the amino acid sequence of SEQ ID NO: 1; a polypeptide having at least 80%... Agent: Reed Smith LLP

20080096797 - Calcium phosphate delivery vehicles for osteoinductive proteins: A composition for delivery of osteogenic proteins is disclosed. The composition comprises an osteogenic protein, a calcium phosphate material as a carrier, and an effective amount of an effervescent agent. Methods of making the compositions and methods of using the osteogenic compositions to treat osteoporotic and/or osteopenic bone are also... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20080096793 - Class iii slrp for the treatment of cancer: There is provided the use of an agent that promotes class III SLRP activity in the manufacture of a medicament for the prevention and/or treatment of cancer. Such medicaments may be used in the treatment of tumours, including avascular tumours. Suitable agents to be used may preferably include the class... Agent: Michael Best & Friedrich LLP

20080096795 - Novel antiangiogenic peptide agents and their therapeutic and diagnostic use: The current invention concerns novel antiangiogenic peptides which correspond to about 10 to about 150 consecutive amino acids of N-terminal sequences of human growth hormone, human placental lactogen, human growth hormone variant hGH-V, and prolactin, and their use in inhibiting angiogenesis and in the diagnosis of diseases of human pregnancy... Agent: Sutherland Asbill & Brennan LLP

20080096794 - Peptide mixture from peptides having a molecular weight of from 1000 to 5000 dalton: The invention relates to the use of a peptide mixture comprising peptides with a molecular weight from 1000 to 5000 Daltons for the prevention and/or treatment of tumour diseases, of diseases which are associated with a development disorder of the immune system, of diseases of the immune system, of autoimmune... Agent: Bacon & Thomas, PLLC

20080096796 - Peptides that stimulate cell survival and axon regeneration: Peptides which consist of or comprise the tetrameric peptide structural unit: Xaa-Xaa-Xaa-Xaa (SEQ.ID.NO.: 1) in which Xaa at position 1 represents Glu or Asp, Xaa at position 2 represents any amino acid, Xaa at position 3 represents any amino acid and Xaa at position 4 represents Glu or Asp, each... Agent: Haynes And Boone, LLP

20080096801 - Compositions and methods for the prevention and control of insulin-induced hypoglycemia: Pharmaceutical composition comprising both insulin and glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia.... Agent: Townsend And Townsend And Crew, LLP

20080096799 - Compounds for and methods of treating insulin resistance and inflammation: Novel compounds, compositions comprising compounds, and methods for preparing and using compounds are described herein. Methods of treating or ameliorating various conditions, including insulin resistance, pancreatic beta cell apoptosis, obesity, pro-thrombotic conditions, myocardial infarction, hypertension, dyslipidemia, manifestations of Syndrome X, congestive heart failure, inflammatory disease of the cardiovascular system, atherosclerosis,... Agent: Kirton And Mcconkie

20080096800 - Rapid mucosal gel or film insulin compositions: Gel, powder, suspension, emulsions or film formulations for systemic delivery of insulin with improved stability and rapid onset of action are described herein. The formulations are preferably absorbed to a mucosal surface, most preferably via buccal or sublingual administration, although rectal, vaginal, nasal or ocular administration is possible. The formulations... Agent: Patrea L. Pabst Pabst Patent Group LLP

20080096802 - Combination therapy comprising glucose reabsorption inhibitors and ppar modulators: Combination therapy comprising PPAR modulators and glucose reabsorption inhibitors useful for the treatment of diabetes and Syndrome X are disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20080096803 - Carboxymethylated cross-linked tetrameric hemoglobin: The present invention includes compositions containing carboxymethylated cross-linked hemoglobin where the cysteine moiety of the hemoglobin includes thiol protecting group and where the hemoglobin is incapable of binding with the nitric oxide. Preferably, the hemoglobin is deoxygenated, endotoxin free, and stroma free. The present invention also includes method of preparation,... Agent: Wilson Sonsini Goodrich & Rosati

20080096804 - Pure amino acid chelate complexes and uses thereof: A two-stage method of preparing essentially pure amino acid chelates, wherein the first stage comprises contacting a metal ion from a metal oxide or hydroxide with an amino acid thereby producing a metal hydroxyl amino acetate. The second stage comprises contacting the metal hydroxyl amino acetate from the first stage,... Agent: Fasken Martineau Dumoulin LLP

20080096806 - Compositions and methods for inhibiting microbial adhesion: The present invention provides compositions and methods for treating or preventing microbial infections.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20080096807 - Cyclic vasoactive intestinal peptide receptor-2 agonists: e

20080096808 - Use of rapamycin to inhibit response and induce tolerance to gene therapy vector and encoded transgene products: Disclosed are methods for transient co-administration of rapamycin together with a gene therapy vector encoding a transgene. The present invention is directed to inhibiting the immune response of a host to the administered gene therapy vector and encoded trans gene product, thus allowing persistent trans gene expression and repeated administration... Agent: Genzyme Corporation Legal Department

20080096819 - Amino acid substituted molecules: The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also... Agent: Seed Intellectual Property Law Group PLLC

20080096821 - Cytostatin ii: The invention relates to cytostatin II growth modulatory polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20080096813 - Generation of potent dominant negative transcriptional inhibitors: The present invention provides methods and compositions for regulating gene expression using transcription factors linked to proteins that localize to the transcriptional machinery.... Agent: Townsend And Townsend And Crew, LLP

20080096817 - Methods of treating disorders of the eye and surrounding tissue with thymosin beta 4 (tbeta4), analogues, isoforms and other derivatives: Eye degradation such as may be associated with dry eye syndrome is inhibited or reversed by administration of an actin-sequestering peptide such as Thymosin β4, an isoform of Thymosin β4 or oxidized Thymosin β4.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20080096814 - Orally administered peptides synergize statin activity: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention... Agent: Beyer Weaver LLP

20080096815 - Orally administered peptides synergize statin activity: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention... Agent: Beyer Weaver LLP

20080096816 - Orally administered peptides synergize statin activity: This invention provides novel peptides that ameliorate one or more symptoms of atherosclerosis. The peptides are highly stable and readily administered via an oral route. The peptides are effective to stimulate the formation and cycling of pre-beta high density lipoprotein-like particles and/or to promote lipid transport and detoxification. This invention... Agent: Beyer Weaver LLP

20080096818 - Prevention and treatment of amyloidogenic disease: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease.... Agent: Townsend And Townsend And Crew, LLP

20080096820 - Prodomain modulators of adam 10: The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20080096822 - Use of the neurotoxic component of a botulinum toxin: A method and composition for treating a patient suffering from a disease, disorder or condition and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.... Agent: Allergan, Inc.

20080096812 - Water-soluble elastin, process for producing same, and food and medicine containing same: A low-molecular-weight water-soluble elastin having a molecular weight of about 10,000 to 30,000 and a high-molecular-weight water-soluble elastin having a molecular weight of about 30,000 to 300,000 are provided, 79% to 84% of the constituent amino acids of the elastin comprising proline, glycine, alanine, and valine, 2% to 3% comprising... Agent: Sughrue Mion, PLLC

20080096823 - Neurotensin receptor agonists and opioid receptor agonists: This document provides methods and materials for treating pain. For example, this document provides methods that involve administering a neurotensin receptor (NTR) agonist and an opioid receptor agonist to a mammal (e.g., a human). Compositions containing an NTR agonist in combination with an opioid receptor agonist also are provided.... Agent: O''melveny & Myers LLP Ip&t Calendar Department La-1118

20080096824 - Ku-70-derived bax-suppressing peptides and use thereof for the protection of damaged cells: A method of protecting cells from cell death comprising the step of supplying to the cell an effective amount of a Bax-inhibiting peptide is disclosed.... Agent: Quarles & Brady LLP

20080096825 - Preparation and use of phlorizin compositions: The present invention concerns the isolation of phlorizin from plants of the genus Lithocarpus, phlorizin-containing compositions and their uses.... Agent: Heller Ehrman LLP

20080096826 - Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments: The present invention provides a novel method for preventing and treating memory and cognitive impairment resulting from oxidative stress, inflammation and the process of aging, as well as, neurodegenerative conditions. The method is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from... Agent: Swanson & Bratschun, L.L.C.

20080096827 - Formulation of a mixture of free-b-ring flavonoids and flavans for use in the prevention and treatment of cognitive decline and age-related memory impairments: The present invention provides a novel method for preventing and treating memory and cognitive impairment resulting from oxidative stress, inflammation and the process of aging, as well as, neurodegenerative conditions. The method is comprised of administering a composition comprising a mixture of Free-B-Ring flavonoids and flavans synthesized and/or isolated from... Agent: Swanson & Bratschun, L.L.C.

20080096828 - 7-quinolyl ketolide antibacterial agents: e

20080096830 - Anti-inflammatory macrolide conjugates: wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, D represents a dibenzo[e,h]azulene subunit with anti-inflammatory, analgesic and/or antipyretic activity and L represents a linking group covalently linking M and D; (b) to their pharmacologically acceptable salts, prodrugs and solvates,... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080096829 - Macrolone compounds: e

20080096832 - Method for improving the pharmacokinetics of an nnrti: An improved method for using a NNRTI in the treatment of HIV-1 infection, comprising administering to a human, needing treatment for HIV-1 infection, a therapeutically effective amount of said NNRTI or a pharmaceutically acceptable salt thereof, and an amount of an inhibitor of the cytochromes P450 that is sufficient to... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20080096831 - Stabilized azithromycin composition: A stabilized azithromycin composition comprising azithromycin monohydrate, and about 5 to about 15 weight percent, based on the total weight of the composition, of water. The present inventors have unexpectedly determined that a certain amount of water is necessary to stabilize a pharmaceutical composition comprising azithromycin monohydrate. In addition, the... Agent: Sandoz Inc

20080096834 - Anti-tumor activity of ea-4-peptide of pro-igf-i: Compositions of pro-IFG-I E-peptides for the treatment and amelioration of tumor-producing diseases, and methods for their utilization.... Agent: Mccarter & English LLP Cityplace I

20080096837 - Defective sindbis viral vectors: Disclosed herein are new defective Sindbis viral vectors made from wild type Ar-339 Sindbis virus, with differences in replicase and envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT and Ar-339 vectors. Also disclosed are plasmids used for the production of the vectors, methods for... Agent: Darby & Darby P.C.

20080096838 - Guanosine rich oligonucleotides and methods of inducing apoptosis in tumor cells: Presently described is a guanosine-rich polynucleotide molecule with therapeutic utility for treating or preventing the growth of cancerous cells. In addition, a method of retarding cell cycle progression and inducing apoptosis in tumor cells using synthetic oligonucleotides is also described.... Agent: Mccarter & English, LLP Basil S. Krikelis

20080096835 - Inhibitory oligonucleotides targeted to bcl-2: Inhibitory oligonucleotides are disclosed which are targeted to three specific target regions and subsequences of the target regions found on nucleic acids encoding Bcl-2. These inhibitory oligonucleotides are generally of from about 8 to about 50 nucleotides in length. Specific preferred oligonucleotides are disclosed. The oligonucleotides of the invention may... Agent: Kenyon & Kenyon LLP

20080096840 - Kinase supressor of ras inactivation for therapy of ras mediated tumorigenesis: The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid... Agent: Klauber & Jackson

20080096836 - Screening method: The invention relates to methods for the identification of novel receptors and/or novel ligands. The invention is based on the concept that parasites have developed a number of biologically active compounds in their saliva to cope with the defense mechanisms of the host organisms on which they feed and to... Agent: Klauber & Jackson

20080096839 - Small interfering rna and pharmaceutical composition for treatment of hepatitis b comprising the same: The present invention relates to RNA interference mediated inhibition of Hepatitis B virus (HBV) by short interfering RNA (siRNA) molecules. Specially, siRNAs of the present invention which are double-stranded RNAs concern directing the sequence-specific degradation of viral RNA in mammalian cells. Disclosed is a DNA vector encoding the RNA molecules... Agent: Sughrue Mion, PLLC

20080096841 - Treatment and prevention of heat shock protein-associated diseases and conditions: The invention provides methods of treating and preventing heat shock protein-associated diseases and conditions.... Agent: Clark & Elbing LLP

20080096842 - Preventive/remedy for obesity: The present invention relates to raw materials for pharmaceuticals and the like, wherein the raw materials can be effective in preventing and remedying various lifestyle-related diseases such as obesity and hyperlipidemia, safe, and applicable in wide areas; and the present invention also relates to a preventive/remedy for obesity, an agent... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080096843 - Substituted isoxazoles as fungicides: The present invention provides compounds of formula I: (I) along with methods of making the same, compositions thereof, and methods of use thereof, particularly methods of use as fungicides.... Agent: Syngenta Crop Protection , Inc. Patent And Trademark Department

20080096844 - Novel inhibitors of chymase: e

20080096845 - Sphingomyelin therapy of autoimmune disease: Autoimmune disease therapy in a patient treated with apoptosis-inducing agents is enhanced by co-administration of sphingomyelin. The combination most likely enhances an autoimmune disease cell's ability to undergo ceramide-induced apoptosis by increasing the levels of sphingomyelin in all cellular compartments, thereby providing sufficient substrate for activated sphingomyelinase. In alternative embodiments,... Agent: Faegre & Benson LLP Patent Docketing

20080096846 - Arene ruthenium (ll) compounds and their use in cancer therapy: A ruthenium (II) compound of formula (I): or a solvate on prodrug thereof, wherein: R1, R1, R3, R4, R5 and R6 are independently selected from H, C1-7 alkyl, C5-20 aryl, C3-20 heterocyclyl, halo, ester, amido, acyl, sulfo, sulfonamido, ether, thioether, azo, amino, or R1 and R2 together with the ring... Agent: Curatolo Sidoti Co., Lpa

20080096847 - Composition and method for inducing or restoring locomotor functions in an animal: The present invention relates to the field of neuropathological disorders involving impaired locomotor functions. More specifically, the present invention relates to a composition and method for inducing and restoring locomotor functions, such as basic walking movements in the lower extremities of chronic spinal cord injured animals, such as paraplegic or... Agent: Baker & Hostetler LLP

20080096849 - Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives: A method of increasing the bioavailability of balsalazide by administration of an oral dosage form with food is provided, as well as an article of manufacture comprising an oral dosage form of balsalazide in a suitable container and associated with printed labeling which describes the increased bioavailability of the medication... Agent: Edwards Angell Palmer & Dodge LLP

20080096848 - Substituted n-aryl-9-oxo-9h-fluorene-1-carboxamides and analogs as activators of caspases and inducers of apoptosis: The present invention is directed to substituted N-aryl-9-oxo-9H-fluorene-1-carboxamides and analogs thereof, represented by the general Formula I: (I) wherein R1-R8, X and Ar are defined herein. The present invention also relates to the discovery that compounds having Formula I are activators of caspases and inducers of apoptosis. Therefore, the activators... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20080096850 - Methods for inhibiting the production of tsst-1: Methods for inhibiting the production of TSST-1 from Gram positive bacteria are disclosed. The methods comprise exposing the Gram positive bacteria to compounds capable of inhibiting the production of TSST-1 from the Gram positive bacteria.... Agent: Christopher M. Goff (27839) Armstrong Teasdale LLP

20080096851 - (20s)-1alpha-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses: This invention discloses (20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such... Agent: Thomas M. Wozny Andrus, Sceales, Starke & Sawall

20080096852 - Use of oculosurface selective glucocorticoid in the treatment of dry eye: Topical ophthalmic compositions and methods for treating dry eye are described. The compositions and methods of the invention are based on the finding that the oculosurface selective properties of the glucocorticoid rimexolone make this anti-inflammatory agent particularly well-suited for treating dry eye. As a result of the limited ability of... Agent: Alcon

20080096854 - Composition and method for treating or preventing gastrointestinal cancer: The present invention provides novel compositions and methods for repair and regeneration of tissues or organs of the body, especially mucosa in the gastrointestinal tract. The composition can be used as a pharmaceutical or nutraceutical to treat or prevent gastrointestinal cancer such as colorectal carcinoma, stomach cancer and esophagus cancer.... Agent: Wilson Sonsini Goodrich & Rosati

20080096853 - Edible compositions comprising a primary lipid, a co-lipid, a lipohilic physiologically active ingredient and water, and their preparation: A composition comprising: a) a primary lipid component obtainable as the reaction product of one or more carboxylic acids with at least one of glycerol and propylene glycol; b) a co-lipid component selected from at least one of phosphorus-containing lipids and hydroxylated carboxylic acid esters of mono- and di-glycerides; c)... Agent: Unilever Intellectual Property Group

20080096855 - Process for obtaining norelgestromin in different relations of isomers e and z: c

20080096856 - Antibiotic compound: Fermentation of a nutrient medium with a Nocardia spp. yields a novel broad spectrum antibiotic compound of structural formula (I) or a pharmaceutically acceptable salt, ester, enantiomer, diasteriomer or mixture.... Agent: Merck And Co., Inc

20080096857 - Photodynamic therapy for the treatment of hyperactive sebaceous gland disorders using topically applied hydrophobic green porphyrins: The present method involves the photodynamic treatment of hyperactive gland disorders. The method involves the topical administration of a photosensitizer composition comprising hydrophobic and/or lipophilic green porphyrins such as lemuteporfin, polyethylene glycol and skin penetration enhancers such as oleyl alcohol and TRANSCUTOL™ to affected skin and subsequent exposure of that... Agent: Morrison & Foerster LLP

20080096858 - Method of stabilizing disordered cefovecin sodium salt: A method of stabilizing pharmaceutical compositions containing cefovecin sodium salt which is in an amorphous or other disordered state is disclosed.... Agent: Pharmacia & Upjohn

20080096859 - Compositions and methods for treating ophthalmic diseases: This invention relates to CXCR4 inhibitors and their use in treating and/or preventing a variety of angiogenic, microvascular and ocular disorders including primary indications for diabetic retinopathy, macular degeneration (such as wet or neovascular age-related macular degeneration (AMD) and dry or atrophic AMD), macular edema, and secondary indications for inhibiting... Agent: Merck And Co., Inc

20080096860 - Pyrimidine sulphonamide derivatives as chemokine receptor modulators: A compound of formula (1), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.... Agent: Fish & Richardson P.C.

20080096861 - Chemical compounds: The present invention provides compounds that demonstrate protective effects on target cells from HIV infection in a manner as to bind to chemokine receptor, and which affect the binding of the natural ligand or chemokine to a receptor such as CXCR4 of a target cell.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B475

20080096863 - Stable pharmaceutical compositions of calcium channel blocker and an ace inhibitor: The present invention relates to a stable pharmaceutical composition of a combination of amlodipine and an ACE inhibitor; wherein the two active ingredients are not physically separated and the composition has a pH of more than 6.0. It also relates to a process for preparation, and a method for using... Agent: Darby & Darby P.C.

20080096864 - Treatment of gastrointestinal stromal tumors with imatinib and midostaurin: The present invention relates to the use of a combination comprising (a) imatinib or a pharmaceutically acceptable salt thereof and midostaurin or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of gastrointestinal stromal tumors, e.g. imatinib-resistant gastro-intestinal stromal tumors.... Agent: Novartis Corporate Intellectual Property

20080096865 - Method for treating neovascularization: The present invention describes an improved photodynamic treatment to treat subfoveal choroidal neovascularization (CNV).... Agent: Novartis Corporate Intellectual Property

20080096866 - Complex formulation of 3-hydroxy-3-methyl glutaryl coa reductace inhibitor and antihypertensive agent, and process for preparing same: A complex formulation for oral administration comprising a sustained release formulation of an HMG-CoA reductase inhib